5/24/2007 | PP | New Issue: NitroMed secures $19.76 million from direct placement of stock
|
5/24/2007 | PP | Market Commentary: NitroMed secures $19.76 million from stock offering; AtriCure pens $16.5 million deal
|
10/11/2006 | BT | NitroMed to replace sales force with cardiovascular specialists
|
10/11/2006 | BT | Market Commentary: Genentech slides, Xoma adds 8%; Genzyme eases; NitroMed sinks; Oscient gains; Northfield loses 3%
|
9/11/2006 | BT | Nitromed to present new data on BiDil to treat heart failure
|
9/8/2006 | BT | Market Commentary: Discovery Labs spikes on buyout buzz; Cell Genesys loses 5% on bought deal; Oscient buffeted
|
9/8/2006 | BT | NitroMed says BiDil XR will be tested in pilot study this year
|
8/3/2006 | BT | Market Commentary: Titan zooms; Vanda slides; LAB goes public in Canada; Indevus up, NitroMed dives
|
5/4/2006 | BT | NitroMed: FDA confirms no equivalent to BiDil
|
5/2/2006 | BT | Market Commentary: Vical top pick in bird flu flock; Noven sinks on profit taking; NitroMed dives, Myriad higher
|
4/11/2006 | BT | Market Commentary: NitroMed, Antigenics strike new lows; NPS Pharma, Insmed gain; Medtronic deal boosts Biomet
|
3/31/2006 | BT | Market Commentary: NitroMed restructuring cheered; Genitope gains on MyVax data; ZymoGenetics up; Panacos off
|
3/30/2006 | BT | NitroMed eliminates 30 R&D positions, seeks partner for cardio-renal compound NMI 3377
|
3/21/2006 | BT | NitroMed CEO, CFO resign, board appoints new senior management
|
3/21/2006 | BT | Market Commentary: Novavax, Nastech buck uptrend in flu names; NitroMed exec exits applauded; BioMarin off on deals
|
3/14/2006 | BT | NitroMed says A-HeFT shows both black women and men benefit from BiDil heart therapy
|
3/13/2006 | BT | Market Commentary: NitroMed off on data; NPS gains 7%; Vasogen falls on trial failure; Medicines up 10%; Myriad higher
|
3/13/2006 | BT | NitroMed's BiDil improves survival of African-American heart patients
|
3/6/2006 | BT | Market Commentary: Cubist players hedging bets with puts; Insmed follow-on emerges; Elan up; Titan zooms; LifeCell up
|
3/3/2006 | BT | Market Commentary: Angiotech to sell bonds, bank debt; Advanced Magnetics rises; Celgene on tear of new highs
|
3/2/2006 | BT | Market Commentary: Genentech recoups from Avastin blow; ImClone slumps; Nastech drops; NitroMed strikes new low
|
3/1/2006 | BT | NitroMed says 2005 revenue down $10.4 million to $6 million
|
1/25/2006 | BT | Market Commentary: Teva launches $2.75 billion bonds; NitroMed pockets $52.6 million; SGX Pharma sweetens IPO talk
|
1/25/2006 | PP | Market Commentary: NitroMed will pocket $62.53 million from direct stock deal; NexMed wraps $8.32 million PIPE
|
1/25/2006 | BTPP | New Issue: NitroMed in deal for $62.53 million direct placement of stock
|
12/30/2005 | BT | NitroMed, Boston Scientific end research program on nitric oxide-enhancing technology
|
11/11/2005 | BT | NitroMed to present further data showing BiDil helps African-Americans with heart failure
|
8/3/2005 | BTCVHY | NitroMed files $250 million debt, stock shelf
|
7/5/2005 | BT | NitroMed obtains $20 million in borrowings
|
6/27/2005 | BT | Market Commentary: CV Therapeutics quiet in gray, Impax Labs refinances converts; Nitromed off; Ligand moves up
|